Japan Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

Japan Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

Japan Professional Acne Medication Market was valued at USD 72.43 million in 2023 and is predicted to reach USD 157.23 million by 2030, with a CAGR of 11.71% from 2024 to 2030. The professional acne medication market encompasses specialized skincare formulations designed and prescribed by dermatologists and skincare professionals to address acne-related concerns. Its primary objectives include providing targeted and effective solutions for various types of acne, such as inflammatory and non-inflammatory lesions, and preventing acne scarring.

The advantages of professional acne medication lie in their potent and tailored formulations, often incorporating clinically proven ingredients that may be more intensive than over-the-counter alternatives. Widely used in dermatology practices, these medications cater to individuals with severe or persistent acne concerns, offering a higher level of efficacy and control. As the demand for advanced skincare solutions rises, the professional acne medication market continues to play a crucial role in promoting clearer, healthier skin through personalized and medically guided approaches.

Strong Healthcare Infrastructure Drives the Market Growth

Professional acne medication market benefits from the country's robust healthcare infrastructure. The availability of advanced medical equipment and a skilled healthcare workforce ensures that patients have access to high-quality care. According to a recent report by the International Trade Administration, Japan's medical device market is expected to exhibit a compound annual growth rate of 5.9% in yen terms from 2021 to 2026. This healthcare infrastructure not only enhances the quality of acne treatment but also contributes significantly to the market's growth by providing patients with the assurance of receiving effective and reliable care for their skin concerns.

 

Supportive Regulatory Environment Driving Growth of the Market

Well established healthcare infrastructure plays a pivotal role in driving the growth of the professional acne medication market. The country's healthcare sector benefits from a supportive regulatory environment, which encourages healthcare access, broader health insurance coverage, and improved affordability of treatments. These initiatives result in enhanced patient access to professional acne care, as well as reducing the financial burden on individuals seeking treatment. This proactive role of the Japanese government ensures that the professional acne medication market continues to thrive and expand. 

 

High Cost Related to Professional Acne Medication Restricting the Growth of the Market

Cost Barriers are a prominent restraining factor affecting the growth of the professional acne medication market in Japan. The country's healthcare system operates with a fee-for-service model, which places a significant portion of medical expenses on patients. This expense issue not only hinders patient access to treatments but also restricts the market's growth.

AI Integration in Dermatology Treatment Creates Future Growth Opportunity for the Market

The integration of AI and technology in dermatology stands as a promising future opportunity for the growth of the professional acne medication market in Japan. AI-driven algorithms have demonstrated their potential to significantly enhance the diagnostic and treatment processes for acne. As these AI solutions evolve, they become more accessible and sophisticated, offering a pathway to improving patient care outcomes. This technological integration is poised to drive the expansion of the market by making acne treatments more effective, convenient, and aligned with the latest advancements in the field.

 

Competitive Landscape

Japan professional acne medication market includes several market players such as Bayer AG, Nestle S.A., Pfizer Inc., Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Galderma S.A., Allergan plc, Stiefel Laboratories Inc., Bausch Health Companies Inc. and others.

Japan Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 72.43 Million

Revenue Forecast in 2030

USD 157.23 Million

Growth Rate

CAGR of 11.71% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Robust healthcare infrastructure

Supportive Healthcare Infrastructure

 Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      JAPAN PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       JAPAN PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       JAPAN PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       JAPAN PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       JAPAN PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. BAYER AG: COMPANY SNAPSHOT

TABLE 19. BAYER AG: OPERATING BUSINESS SEGMENTS

TABLE 20. BAYER AG: PRODUCT PORTFOLIO

TABLE 21. BAYER AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. BAYER AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. BAYER AG: KEY STRATERGY

TABLE 24. NESTLE S.A.: COMPANY SNAPSHOT

TABLE 25. NESTLE S.A.: OPERATING BUSINESS SEGMENTS

TABLE 26. NESTLE S.A.: PRODUCT PORTFOLIO

TABLE 27. NESTLE S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. NESTLE S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. NESTLE S.A.: KEY STRATERGY

TABLE 30. PFIZER INC.: COMPANY SNAPSHOT

TABLE 31. PFIZER INC.: OPERATING BUSINESS SEGMENTS

TABLE 32. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 33. PFIZER INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. PFIZER INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. PFIZER INC.: KEY STRATERGY

TABLE 36. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 37. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 38. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 39. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 42. ROCHE HOLDING AG: COMPANY SNAPSHOT

TABLE 43. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS

TABLE 44. ROCHE HOLDING AG: PRODUCT PORTFOLIO

TABLE 45. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. ROCHE HOLDING AG: KEY STRATERGY

TABLE 48. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 49. GLAXOSMITHKLINE PLC: OPERATING BUSINESS SEGMENTS

TABLE 50. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 51. GLAXOSMITHKLINE PLC: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. GLAXOSMITHKLINE PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. GLAXOSMITHKLINE PLC: KEY STRATERGY

TABLE 54. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 55. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 56. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 57. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. GALDERMA S.A.: KEY STRATERGY

TABLE 60. ALLERGAN PLC: COMPANY SNAPSHOT

TABLE 61. ALLERGAN PLC: OPERATING BUSINESS SEGMENTS

TABLE 62. ALLERGAN PLC: PRODUCT PORTFOLIO

TABLE 63. ALLERGAN PLC: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. ALLERGAN PLC: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. ALLERGAN PLC: KEY STRATERGY

TABLE 66. STIEFEL LABORATORIES INC.: COMPANY SNAPSHOT

TABLE 67. STIEFEL LABORATORIES INC.: OPERATING BUSINESS SEGMENTS

TABLE 68. STIEFEL LABORATORIES INC.: PRODUCT PORTFOLIO

TABLE 69. STIEFEL LABORATORIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. STIEFEL LABORATORIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. STIEFEL LABORATORIES INC.: KEY STRATERGY

TABLE 72. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 73. BAUSCH HEALTH COMPANIES INC.: OPERATING BUSINESS SEGMENTS

TABLE 74. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 75. BAUSCH HEALTH COMPANIES INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. BAUSCH HEALTH COMPANIES INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. JAPAN PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. BAYER AG: NET SALES, (2021-2023)

FIGURE 24. BAYER AG: PRIMARY MARKET COMPETITORS

FIGURE 25. NESTLE S.A.: NET SALES, (2021-2023)

FIGURE 26. NESTLE S.A.: PRIMARY MARKET COMPETITORS

FIGURE 27. PFIZER INC.: NET SALES, (2021-2023)

FIGURE 28. PFIZER INC.: PRIMARY MARKET COMPETITORS

FIGURE 29. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 30. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 31. ROCHE HOLDING AG: NET SALES, (2021-2023)

FIGURE 32. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS

FIGURE 33. GLAXOSMITHKLINE PLC: NET SALES, (2021-2023)

FIGURE 34. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS

FIGURE 35. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 36. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 37. ALLERGAN PLC: NET SALES, (2021-2023)

FIGURE 38. ALLERGAN PLC: PRIMARY MARKET COMPETITORS

FIGURE 39. STIEFEL LABORATORIES INC.: NET SALES, (2021-2023)

FIGURE 40. STIEFEL LABORATORIES INC.: PRIMARY MARKET COMPETITORS

FIGURE 41. BAUSCH HEALTH COMPANIES INC.: NET SALES, (2021-2023)

FIGURE 42. BAUSCH HEALTH COMPANIES INC.: PRIMARY MARKET COMPETITOR

KEY PLAYERS

  • Bayer AG

  • Nestle S.A.

  • Pfizer Inc.

  • Johnson & Johnson

  • Roche Holding AG

  • GlaxoSmithKline plc

  • Galderma S.A.

  • Allergan plc

  • Stiefel Laboratories Inc.

  • Bausch Health Companies Inc.


Frequently Asked Questions
What will be the worth of the Japan professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the Japan professional acne medication market business is expected to hit at USD 157.23 million by 2030.

What are the leading companies in the Japan professional acne medication market?

The Japan professional acne medication industry includes several market players such as Bayer AG, Nestle S.A., Pfizer Inc., Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Galderma S.A., Allergan plc, Stiefel Laboratories Inc., Bausch Health Companies Inc.and others.

What are the market segmentations and scope of the study for the Japan professional acne medication industry?

Japan professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in Japan?

The factors driving the growth of the professional acne medication market in Japan include robust healthcare infrastructure and government policies and regulations.

What is restraining the growth of the Japan professional acne medication market?

The cost barriers are prominent restraining factors in Japan's posing a significant challenge to its expansion.